Key statistics
On Monday, Altamira Therapeutics Ltd (CYTO:NAQ) closed at 0.668, 0.00% above its 52-week low of 0.668, set on Sep 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.72 |
---|---|
High | 0.75 |
Low | 0.668 |
Bid | 0.668 |
Offer | 0.75 |
Previous close | 0.7102 |
Average volume | 103.44k |
---|---|
Shares outstanding | 3.78m |
Free float | 3.38m |
P/E (TTM) | -- |
Market cap | 2.52m USD |
EPS (TTM) | -27.56 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 20:59 BST.
More ▼
- Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
- Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
- Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
- Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
- Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
- Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
- Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
- Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
- Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
- Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
More ▼